Janssen Pharmaceutical Release: New XARELTO (Rivaroxaban) Data At ESC Congress 2017 Includes Late-Breaking Results From Landmark Phase III COMPASS Study

TITUSVILLE, N.J., Aug. 21, 2017 /PRNewswire/ -- New data from the landmark Phase 3 COMPASS study evaluating the use of XARELTO® (rivaroxaban) in coronary and peripheral artery disease (CAD and PAD) are among the 25 presentations from Janssen Research & Development, LLC (Janssen) and its development partner Bayer to be featured at the ESC Congress 2017 in Barcelona, Spain. In addition to two late-breaking presentations from the COMPASS study, the companies will present sub-analyses from PIONEER AF-PCI, a study of XARELTO® in patients with non-valvular atrial fibrillation (NVAF) following percutaneous coronary intervention (PCI) with stenting.

Back to news